Protocol Ledger

NCT06510816 · Phase III · ACTIVE NOT RECRUITING

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Interventional Phase III clinical trial protocol NCT06510816 sponsored by Annexon in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-30 Enrollment: 659 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06510816
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)659 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06510816
Protocol FieldVerified Registry Value
NCT IdentifierNCT06510816
Consolidated Lead SponsorAnnexon
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment659 participants (ACTUAL)
Registered Start Date2024-07-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06510816
Hospital Research SiteLocationSite Profile
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->
Global Research ManagementGlendale, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI